Breaking U.S. Beef Prices to Be Lowered for 90 Days Through Import Deal PWHL Championship Trophy Missing in Transit to Alberta Trump Ally Ed Martin Departs Justice Department for Election Legal Battles California Fines Backcountry Guide Company $151,300 After Deadly Avalanche National Park Service Projects Delayed Amid White House Initiative Prioritization

Friday August 21, 2026

Reporter

LEADS BIOLABS CO., LTD.

7Articles Published

5Communities Covered

Published Articles

Press Release

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement

Aug 20

Press Release

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement

Aug 20

Press Release

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement

Aug 20

Press Release

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals

Aug 5

Press Release

Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL‑051 for Refractory Autoimmune Diseases

Aug 4

Press Release

Leads Biolabs’ PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise

Aug 2

Press Release

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Completes Patient Enrollment in Phase II Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors

Jul 30